RxDoctor Payments Data

Ravi Bhatia, MD

Hematology · Duarte, CANPI 1326059700

Payments from drug & device makers

$275,055in general payments, 2019–2025

Across 45 payments — averaging $6112.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Co., Ltd.$176K
  • Amgen$99K
  • Gilead$18
  • Pfizer$16

What the payments were for

  • Food & beverage$3569%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka Pharmaceutical Co., Ltd.37$176,279
Amgen6$98,742
Gilead1$18
Pfizer1$16

How this compares

$275,055 in reported general payments places this provider in the 60th percentile of 178 hematology providers in California.

See all hematology providers in California

Medicare billing

Part B allowed, 2024
$22,326
Medicare patients
44
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BosulifBosutinib35$312,505
IclusigPonatinib Hcl11$238,204
SprycelDasatinib14$228,694
Imatinib Mesylate62$103,418
Deferasirox16$95,374
Hydroxyurea25$721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerBosulif$16$312,50535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 178 hematology providers in California.

Other hematology in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →